BB Biotech Past Earnings Performance
Past criteria checks 1/6
BB Biotech's earnings have been declining at an average annual rate of -23.1%, while the Capital Markets industry saw earnings growing at 8.9% annually. Revenues have been declining at an average rate of 27.3% per year. BB Biotech's return on equity is 12.4%, and it has net margins of 113.7%.
Key information
-23.1%
Earnings growth rate
-23.2%
EPS growth rate
Capital Markets Industry Growth | 10.7% |
Revenue growth rate | -27.3% |
Return on equity | 12.4% |
Net Margin | 113.7% |
Next Earnings Update | 26 Jul 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How BB Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 24 | 271 | 308 | 29 | 0 |
31 Dec 23 | 0 | -207 | 30 | 0 |
30 Sep 23 | 0 | -351 | 33 | 0 |
30 Jun 23 | 0 | -92 | 35 | 0 |
31 Mar 23 | 0 | -312 | 37 | 0 |
31 Dec 22 | 0 | -358 | 39 | 0 |
30 Sep 22 | -187 | -869 | 42 | 0 |
30 Jun 22 | -380 | -1,287 | 47 | 0 |
31 Mar 22 | -236 | -926 | 50 | 0 |
31 Dec 21 | 0 | -405 | 53 | 0 |
30 Sep 21 | 867 | 806 | 51 | 0 |
30 Jun 21 | 677 | 619 | 48 | 0 |
31 Mar 21 | 1,724 | 1,670 | 45 | 0 |
31 Dec 20 | 742 | 691 | 42 | 0 |
30 Sep 20 | 581 | 532 | 41 | 0 |
30 Jun 20 | 964 | 545 | 41 | 0 |
31 Mar 20 | -598 | -970 | 41 | 0 |
31 Dec 19 | 728 | 677 | 42 | 0 |
30 Sep 19 | -43 | -471 | 42 | 0 |
30 Jun 19 | 211 | 153 | 42 | 0 |
31 Mar 19 | 582 | 390 | 42 | 0 |
31 Dec 18 | 5 | -471 | 42 | 0 |
30 Sep 18 | 114 | 16 | 42 | 0 |
30 Jun 18 | 234 | 139 | 41 | 0 |
31 Mar 18 | 347 | 341 | 39 | 0 |
31 Dec 17 | 730 | 688 | 38 | 0 |
30 Sep 17 | 875 | 819 | 40 | 0 |
30 Jun 17 | 901 | 846 | 38 | 0 |
31 Mar 17 | 433 | 778 | 37 | 0 |
31 Dec 16 | 9 | -802 | 37 | 0 |
30 Sep 16 | 530 | -266 | 34 | 0 |
30 Jun 16 | 130 | -1,234 | 36 | 0 |
31 Mar 16 | 265 | -932 | 37 | 0 |
31 Dec 15 | 697 | 653 | 38 | 0 |
30 Sep 15 | 908 | 868 | 36 | 0 |
30 Jun 15 | 1,397 | 1,926 | 32 | 0 |
31 Mar 15 | 1,818 | 1,784 | 27 | 0 |
31 Dec 14 | 1,498 | 1,470 | 23 | 0 |
30 Sep 14 | 867 | 844 | 16 | 0 |
30 Jun 14 | 722 | 700 | 15 | 0 |
31 Mar 14 | 660 | 639 | 14 | 0 |
31 Dec 13 | 950 | 932 | 13 | 0 |
30 Sep 13 | 719 | 697 | 14 | 0 |
30 Jun 13 | 529 | 507 | 14 | 0 |
Quality Earnings: BIOEE has a large one-off gain of CHF76.6M impacting its last 12 months of financial results to 31st March, 2024.
Growing Profit Margin: BIOEE became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BIOEE's earnings have declined by 23.1% per year over the past 5 years.
Accelerating Growth: BIOEE has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: BIOEE has become profitable in the last year, making it difficult to compare its past year earnings growth to the Capital Markets industry (6%).
Return on Equity
High ROE: BIOEE's Return on Equity (12.4%) is considered low.